文献速递系统性红斑狼疮

系统性红斑狼疮孕妇暴露于硫唑嘌呤增加妊娠期肝内胆汁淤积症风险

Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine.
PubMed 文献 · Arthritis Rheumatol · 2026-05-04

在多中心前瞻性LEGACY队列中,127例系统性红斑狼疮(SLE)妊娠中,46例暴露于硫唑嘌呤(AZA)、81例未暴露,共发生10例妊娠期肝内胆汁淤积症(ICP)。AZA暴露与ICP风险显著增加相关(调整风险比12.1,95%CI 2.4-59.7),且所有有代谢物数据的ICP病例均显示孕中期硫嘌呤分流。

要点

  • SLE孕妇AZA暴露者ICP发生率为17.4%,未暴露者为2.5%。
  • AZA暴露与ICP风险显著相关,调整风险比12.1(95%CI 2.4-59.7)。
  • 孕中期硫嘌呤分流可能识别ICP高危孕妇,支持代谢物监测价值。

核心结论

  • AZA暴露可能与SLE妊娠中ICP强烈相关。
  • 孕中期硫嘌呤分流可能识别ICP高危女性,支持代谢物监测的价值。

研究设计与样本

  • LEGACY为在加拿大、韩国、秘鲁和墨西哥的系统性红斑狼疮国际协作组开展的多中心前瞻性队列。
  • 纳入孕17周前的SLE孕妇,在孕中期(20-24周)、孕晚期(30-34周)和产后(8-12周)随访;因ICP发生于20周后,仅纳入有孕中期访视的妊娠,随访从该访视至分娩。
  • AZA暴露建模为时变变量,主要结局为因ICP的医源性分娩或ICP诊断后发生的自发性早产,采用多变量Cox模型(含frailty)调整相关协变量。
  • 蒙特利尔站点评估硫嘌呤代谢物及分流。

主要发现

  • 127例SLE妊娠中(46例AZA暴露,81例未暴露),共发生10例ICP(每例为不同女性):AZA暴露组8例(17.4%,95%CI 9.1-30.7),未暴露组2例(2.5%,95%CI 0.7-8.6)。
  • AZA暴露与ICP风险显著增加相关(调整风险比12.1,95%CI 2.4-59.7)。
  • 所有有代谢物数据的ICP病例(4/4)显示孕中期分流。
  • 在所有有孕中期代谢物数据的妊娠(n=22)中,36.4%(95%CI 19.7-57.0)存在分流,其中50.0%(95%CI 21.5-78.5)发生ICP。

关键数值与推荐

  • AZA暴露组ICP发生率17.4%(95%CI 9.1-30.7),未暴露组2.5%(95%CI 0.7-8.6)。
  • AZA暴露与ICP的调整风险比12.1(95%CI 2.4-59.7)。
  • 有孕中期代谢物数据的妊娠中分流比例36.4%(95%CI 19.7-57.0),分流者ICP发生率50.0%(95%CI 21.5-78.5)。

临床怎么用

  • 对SLE妊娠女性使用AZA时,应警惕ICP风险,可能需加强监测。
  • 孕中期硫嘌呤代谢物监测或有助于识别ICP高危孕妇。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)-exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. METHODS: LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru, and Mexico. Pregnant women with SLE are enrolled before 17 weeks and followed in the second (20-24 weeks) and third (30-34 weeks) trimesters and postpartum (8-12 weeks). Because ICP occurs after 20 weeks, only pregnancies with a second-trimester visit were included. Follow-up began at that visit and continued until delivery. AZA exposure was modeled as time varying. The primary outcome was iatrogenic delivery for ICP or spontaneous preterm birth occurring after ICP diagnosis. Multivariable Cox models with frailties adjusted for relevant covariates. At the Montreal site, thiopurine metabolites and shunting were assessed. RESULTS: Among 127 SLE pregnancies (46 AZA exposed, 81 unexposed), 10 ICP cases occurred (each in a distinct woman): 8 among AZA exposed (17.4%, 95% confidence interval [CI] 9.1-30.7) and 2 among unexposed (2.5%, 95% CI 0.7-8.6). AZA exposure was associated with a substantially increased risk of ICP (adjusted hazard ratio 12.1, 95% CI 2.4-59.7). All ICP cases with metabolite data (4 of 4) showed second-trimester shunting. Among all pregnancies with second-trimester metabolite data (n = 22), 36.4% (95% CI 19.7-57.0) were shunting, and 50.0% (95% CI 21.5-78.5) of these developed ICP. CONCLUSION: We observed that AZA exposure may be strongly associated with ICP in SLE pregnancies. Second-trimester thiopurine shunting may identify women at high risk, supporting the value of metabolite monitoring.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Farhat R, Zamora-Medina MDC, Bae SC, et al. Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine. Arthritis Rheumatol. 2026. PMID: 42080644. doi:10.1002/art.70208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。